SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Dynogen Pharmaceuticals
Dynogen developed a portfolio of therapies for gastrointestinal and genitourinary disorders. It went out of business in 2009.
Dynogen Pharmaceuticals
Waltham, MA
